Please login to the form below

Not currently logged in
Email:
Password:

MHRA names vice-chair of Commission on Human Medicines

Angela Thomas is a consultant paediatric haematologist

Angela Thomas, MHRAThe UK's medicines regulator has appointed Dr Angela Thomas as vice chair of its Commission on Human Medicines (CHM).

Dr Thomas replaces Prof Ian Weller who retires from the body, which advises the Medicines and Healthcare products Regulatory Agency (MHRA) on drug safety and efficacy.

“I am delighted to be taking up this new role,” said Dr Thomas. “The Commission plays a vital role in the licensing of new medicines and in monitoring drug safety.”

Dr Thomas is an experienced healthcare professional and currently works as a consultant paediatric haematologist at the Royal Hospital for Sick Children in Edinburgh.

She is also a fellow of the Royal College of Physicians in Edinburgh, a former president of the British Society for Haematology and has been on the CHM since 2005, where she chairs the clinical trials, biologicals and vaccines expert advisory Group.

In her new role she will help lead the CHM regarding the advice it gives on applications for both national and European marketing authorisations. Commissioners also frequently attend the European Committee on Human Medicinal Products (CHMP) meetings as part of the UK delegation.

20th January 2015

From: Regulatory, Healthcare

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics